Texas Hemp-THC Ban: Legal Battle, Industry Impact & Consumer Rights

Executive Summary

Texas is engaged in a high-stakes legal and regulatory battle to ban hemp-derived THC products, a fight that could reshape the $28 billion U.S. hemp industry and set a precedent for how states regulate intoxicating cannabinoids sold outside traditional cannabis programs. The conflict centers on delta-8 THC, delta-10 THC, THCA, and other psychoactive compounds derived from hemp that proliferated after the 2018 Farm Bill federally legalized hemp containing less than 0.3% delta-9 THC. Texas lawmakers passed House Bill 1325 in 2019 to align with federal hemp law, but the unintended consequence was a booming market for intoxicating hemp products sold in gas stations, vape shops, and online retailers without the testing, labeling, or age verification requirements imposed on state-licensed medical cannabis. In 2023, the Texas Department of State Health Services (DSHS) attempted to ban delta-8 and other hemp-derived cannabinoids by adding them to the state's controlled substances schedule, sparking immediate legal challenges from hemp manufacturers and retailers. As of May 2026, the case remains in litigation, with industry groups arguing the ban violates the 2018 Farm Bill's supremacy over state law, while Texas officials contend they retain authority to regulate intoxicating substances regardless of their source plant. The outcome will determine whether Texas's estimated 2,400 hemp retailers can continue operating, whether consumers retain access to products many use for anxiety and pain management, and whether other conservative states follow Texas's regulatory approach.

Why This Matters

The Texas hemp-THC ban affects a $800 million in-state market, thousands of small businesses, millions of consumers, and the national legal framework governing hemp-derived cannabinoids. For consumers, the ban would eliminate access to products that an estimated 2.1 million Texans have purchased since 2019, according to industry surveys. Many users report relying on delta-8 THC and THCA for conditions including chronic pain, anxiety, insomnia, and nausea—often because they cannot access the state's restrictive Compassionate Use Program, which limits medical cannabis to patients with specific qualifying conditions and caps THC content at 1%. A complete ban would force these consumers toward either the illicit market or no treatment at all. For businesses, the stakes are existential. Texas hemp retailers generated an estimated $800 million in sales in 2025, supporting approximately 12,000 jobs across cultivation, manufacturing, distribution, and retail. Small business owners invested hundreds of thousands of dollars in inventory, equipment, and leases based on the legal framework established by HB 1325. A sudden ban would render that inventory worthless overnight and force mass closures, particularly among the independent vape shops and CBD stores that pivoted to hemp-THC products as their primary revenue source. For the broader hemp industry, Texas represents the largest market among states without adult-use cannabis programs. The state's decision carries outsize influence—if Texas successfully bans hemp-THC despite the 2018 Farm Bill, other conservative states including Florida, Georgia, and Tennessee are likely to follow. Conversely, if courts strike down the Texas ban as preempted by federal law, it would strengthen the legal foundation for hemp-THC products nationwide and potentially accelerate their growth in the estimated 23 states currently allowing their sale. For medical cannabis operators, the ban represents a competitive question. Texas's three licensed medical cannabis dispensaries—Compassionate Cultivation, Goodblend Texas, and Rise HTX—have advocated for stricter hemp regulation, arguing that untested gas station products undermine the safety standards and patient protections built into the Compassionate Use Program. These operators view hemp-THC as unregulated competition that siphons potential patients and revenue from the licensed system. The legal precedent extends beyond Texas. Federal courts have not definitively ruled on whether the 2018 Farm Bill's legalization of hemp preempts state authority to ban specific hemp-derived cannabinoids. The Texas case could establish binding precedent in the Fifth Circuit and persuasive authority nationwide, shaping how states balance federal hemp law against traditional police powers to regulate intoxicating substances.

Background and History

The Texas hemp-THC controversy stems from a regulatory gap created when federal and state lawmakers legalized hemp without anticipating the market for intoxicating derivatives.

The 2018 Farm Bill and Federal Hemp Legalization

The Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill, removed hemp from the Controlled Substances Act's definition of marijuana. The law defined hemp as Cannabis sativa L. containing no more than 0.3% delta-9 THC on a dry weight basis, effectively legalizing hemp cultivation, processing, and sales at the federal level. The bill's sponsors, including Senate Majority Leader Mitch McConnell, framed hemp legalization as an agricultural opportunity for farmers to grow a crop used in textiles, construction materials, and CBD wellness products. The 0.3% threshold was based on a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who proposed the concentration as an arbitrary dividing line between hemp and marijuana for botanical classification purposes—not as a policy recommendation for intoxication potential. The 2018 Farm Bill adopted this threshold without accounting for the fact that hemp could be chemically converted into intoxicating cannabinoids or that certain cannabinoids like THCA convert to delta-9 THC when heated.

Texas House Bill 1325 (2019)

In 2019, the Texas Legislature passed House Bill 1325 to align state law with the 2018 Farm Bill. The bill, signed by Governor Greg Abbott on June 10, 2019, legalized hemp cultivation and removed hemp from the state's controlled substances definitions. The law defined hemp identically to federal law—cannabis containing not more than 0.3% delta-9 THC—and authorized the Texas Department of Agriculture to regulate hemp farming. HB 1325's passage had an immediate unintended consequence: it created legal ambiguity around marijuana possession cases. Because hemp and marijuana are visually identical and distinguishable only through laboratory testing for THC concentration, prosecutors could no longer prove beyond a reasonable doubt that a substance was marijuana rather than legal hemp. District attorneys in Harris County, Travis County, and other jurisdictions announced they would dismiss misdemeanor marijuana possession cases, leading to the dismissal of thousands of pending charges. This prosecutorial crisis prompted calls for regulatory clarification, but lawmakers did not anticipate the coming wave of intoxicating hemp products.

The Rise of Delta-8 THC (2020-2021)

In 2020, chemists and hemp manufacturers discovered they could convert CBD extracted from legal hemp into delta-8 THC through a chemical process involving acids and heat. Delta-8 THC is a naturally occurring cannabinoid found in cannabis plants in trace amounts, but the commercial products flooding the market were semi-synthetic—created by isomerizing CBD into delta-8 through chemical reactions. Delta-8 THC produces psychoactive effects similar to delta-9 THC but is generally reported as less potent and less anxiety-inducing. Because delta-8 products were derived from legal hemp and contained less than 0.3% delta-9 THC, manufacturers argued they were legal under both the 2018 Farm Bill and Texas HB 1325. The products appeared in vape shops, smoke shops, and gas stations across Texas in 2021, marketed as legal alternatives to marijuana. The market exploded rapidly. By late 2021, an estimated 800 Texas retailers were selling delta-8 products, generating approximately $200 million in annual sales. Products included vape cartridges, gummies, tinctures, and flower sprayed with delta-8 distillate. The retail environment ranged from specialty CBD stores with knowledgeable staff to gas stations selling products next to energy drinks, often without age verification or product information.

Texas DSHS Attempted Ban (October 2021)

On October 15, 2021, the Texas Department of State Health Services published a notice in the Texas Register announcing its intent to add delta-8 THC, delta-9 THC, and other tetrahydrocannabinols to the state's Schedule I controlled substances list. DSHS argued that delta-8 THC met the definition of a Schedule I substance as a "tetrahydrocannabinol" and that the agency retained authority to schedule controlled substances regardless of their source. The announcement triggered immediate backlash. The Hometown Hero CBD company, a Houston-based hemp manufacturer, filed a lawsuit in Travis County district court on October 20, 2021, seeking a temporary restraining order to block the ban. On October 21, 2021, Judge Jan Soifer granted the restraining order, preventing DSHS from enforcing the ban while the case proceeded. In her order, Judge Soifer found that plaintiffs demonstrated probable success on the merits, noting that HB 1325 appeared to legalize all hemp-derived products containing less than 0.3% delta-9 THC and that DSHS's interpretation conflicted with the statute's plain language. The temporary restraining order was later converted to a temporary injunction, keeping delta-8 and other hemp-THC products legal in Texas while litigation continued.

Legislative Attempts at Regulation (2023)

During the 2023 Texas legislative session, lawmakers introduced multiple bills attempting to regulate hemp-THC products rather than ban them outright. Senate Bill 1698, filed by Senator Charles Perry, proposed creating a regulatory framework for hemp-derived consumables, including age restrictions, testing requirements, and labeling standards. House Bill 2593 proposed similar regulations with a 21-and-older age requirement and mandatory COA (certificate of analysis) testing. Both bills died in committee without reaching a floor vote. Observers attributed the failure to competing interests: medical cannabis licensees lobbied for stricter restrictions or outright bans to eliminate competition, while hemp retailers opposed regulations they viewed as too burdensome for small businesses. Law enforcement groups supported bans, citing concerns about impaired driving and youth access, while patient advocates argued that hemp-THC products provided access to relief for Texans excluded from the restrictive Compassionate Use Program. The legislative stalemate left the regulatory status quo unchanged, with hemp-THC products remaining legal under the 2021 court injunction but operating in a gray area without specific safety regulations.

DSHS Renewed Ban Effort (2024-2025)

In March 2024, DSHS published a new proposed rule to ban delta-8 THC, delta-10 THC, THCP, THCO, and other hemp-derived intoxicating cannabinoids. The agency argued that these substances were "synthetically derived tetrahydrocannabinols" that fell outside the 2018 Farm Bill's protection for naturally occurring hemp compounds. DSHS cited concerns about product safety, lack of testing standards, youth access, and reports of adverse events including hospitalizations. The proposed rule underwent a public comment period that generated over 18,000 comments, with approximately 92% opposing the ban according to DSHS's summary. Commenters included consumers describing medical benefits, small business owners detailing economic impacts, and hemp industry groups arguing the rule violated federal law. Supporting comments came primarily from law enforcement, medical cannabis operators, and parents concerned about youth access. On November 1, 2024, DSHS published the final rule adding hemp-derived THC isomers to Schedule I, with an effective date of January 1, 2025. Within hours, a coalition of hemp companies including Hometown Hero, Bayou City Hemp Company, and the Texas Hemp Coalition filed suit in Travis County district court seeking declaratory and injunctive relief. On December 18, 2024, Judge Karin Crump issued a temporary injunction blocking enforcement of the ban, finding that plaintiffs demonstrated a substantial likelihood of success on their claims that the rule conflicted with HB 1325 and was preempted by the 2018 Farm Bill. The injunction remains in effect as of May 2026, allowing hemp-THC sales to continue while the case proceeds through discovery and toward trial.

Key Players

Texas Department of State Health Services (DSHS)

DSHS is the state agency responsible for scheduling controlled substances in Texas under Chapter 481 of the Texas Health and Safety Code. The agency has defended its authority to ban hemp-derived THC products by arguing that its scheduling power extends to all intoxicating substances regardless of source plant, and that semi-synthetic cannabinoids created through chemical conversion fall outside the 2018 Farm Bill's protection. DSHS Commissioner Jennifer Shuford has cited public health concerns including lack of testing standards, inconsistent labeling, and emergency room visits related to hemp-THC consumption.

Hometown Hero CBD

Founded in 2015 and based in Austin, Hometown Hero is one of Texas's largest hemp-THC manufacturers and has served as lead plaintiff in both the 2021 and 2024 lawsuits challenging DSHS bans. The company operates retail locations across Texas and sells products online nationwide. CEO Lukas Gilkey has been a vocal advocate for hemp industry interests, arguing that DSHS's ban attempts violate legislative intent and federal supremacy.

Texas Hemp Coalition

The Texas Hemp Coalition is an industry trade group representing hemp farmers, processors, manufacturers, and retailers across the state. The organization has coordinated legal challenges to the DSHS ban, lobbied the legislature for regulatory frameworks, and advocated for consumer access to hemp-THC products. The coalition estimates its members represent over $800 million in annual economic activity and 12,000 jobs.

Texas Department of Agriculture

The Texas Department of Agriculture, led by Commissioner Sid Miller, regulates hemp cultivation in Texas under authority granted by HB 1325. Miller has publicly opposed DSHS's ban attempts, arguing that hemp is an agricultural commodity that should be regulated for safety rather than prohibited. The agency has issued over 3,000 hemp cultivation licenses since 2019 and views the crop as an economic opportunity for Texas farmers.

Texas Medical Cannabis Operators

Texas's three licensed medical cannabis dispensaries—Compassionate Cultivation, Goodblend Texas, and Rise HTX—operate under the state's Compassionate Use Program, which requires extensive testing, security, and tracking systems. These operators have supported stricter hemp regulation, arguing that untested hemp-THC products create unfair competition and undermine patient safety. The operators invested tens of millions of dollars in licensed facilities and view hemp retailers as operating outside the regulatory framework they must follow.

Governor Greg Abbott

Governor Abbott signed HB 1325 into law in 2019 but has not taken a public position on the hemp-THC ban controversy. His office has deferred questions to DSHS and the legislature. Abbott has historically opposed adult-use cannabis legalization but supported the limited medical cannabis program, leaving his stance on hemp-THC ambiguous.

Texas Legislature

The Texas Legislature's failure to pass hemp-THC regulation during the 2023 and 2025 sessions has left the issue to courts and agencies. Key legislators including Senator Perry and Representative Stephanie Klick have expressed support for age restrictions and testing requirements but have not built sufficient consensus for passage. The 2027 legislative session, beginning in January 2027, represents the next opportunity for statutory clarification.

Legal and Regulatory Framework

The Texas hemp-THC ban rests on a complex interplay of federal drug scheduling, state controlled substances law, and constitutional preemption doctrine. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use and abuse potential. Schedule I includes substances with high abuse potential and no accepted medical use, including marijuana. The CSA defines marijuana as "all parts of the plant Cannabis sativa L." but excludes "the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks." The 2018 Farm Bill amended the CSA's marijuana definition to exclude "hemp," defined as Cannabis sativa L. containing not more than 0.3% delta-9 THC on a dry weight basis. This amendment, codified at 7 U.S.C. § 1639o, removed hemp from Schedule I and legalized it for cultivation, processing, and interstate commerce. The law explicitly states that hemp is not a controlled substance. Texas Health and Safety Code Chapter 481 establishes the state's controlled substances schedules, which generally mirror federal schedules. Section 481.002 defines "marihuana" using language similar to the federal CSA, and HB 1325 amended this definition to exclude hemp as defined by federal law. Section 481.034 authorizes DSHS to add substances to Schedule I by rule if they meet statutory criteria. The central legal question is whether DSHS's authority to schedule controlled substances extends to hemp-derived cannabinoids that meet the federal definition of hemp. DSHS argues that delta-8 THC and similar compounds are "synthetically derived tetrahydrocannabinols" that fall outside hemp's legal definition because they are created through chemical conversion rather than natural extraction. The agency cites the DEA's August 2020 interim final rule, which stated that "synthetically derived tetrahydrocannabinols remain Schedule I controlled substances." Hemp industry plaintiffs counter that the 2018 Farm Bill and HB 1325 legalized all derivatives, extracts, and cannabinoids derived from hemp containing less than 0.3% delta-9 THC, regardless of processing method. They argue that chemical conversion does not make a hemp-derived compound "synthetic" if the source material is legal hemp and the final product meets the THC threshold. Plaintiffs also assert that federal law preempts state attempts to ban hemp-derived products, citing the Supremacy Clause of the U.S. Constitution, Article VI, Clause 2. The preemption argument faces counterarguments based on federalism principles. The CSA explicitly preserves state authority to enact more restrictive controlled substances laws under 21 U.S.C. § 903, which states that the CSA does not preempt state law unless there is a "positive conflict" such that the two cannot consistently stand together. Texas argues that no positive conflict exists because the state is exercising its traditional police power to regulate intoxicating substances, and the 2018 Farm Bill did not expressly prohibit states from banning specific hemp-derived cannabinoids. Case law on hemp preemption remains limited. In Atalo Holdings v. O'Scanlon (D.N.J. 2022), a federal district court rejected a preemption challenge to New Jersey's ban on delta-8 THC, finding that the state's prohibition did not conflict with federal hemp law. However, that decision is not binding in Texas, and other courts have not addressed the issue. The Texas litigation also raises questions under the state Administrative Procedure Act, codified at Texas Government Code Chapter 2001. Plaintiffs argue that DSHS's rule exceeds the agency's statutory authority because the legislature specifically legalized hemp in HB 1325, and agencies cannot override legislative policy choices through rulemaking. This argument invokes the nondelegation doctrine and statutory interpretation principles requiring agencies to implement rather than contradict legislative intent.

State-by-State Breakdown of Hemp-THC Regulation

States have adopted widely divergent approaches to regulating hemp-derived intoxicating cannabinoids, creating a patchwork legal landscape.

States That Have Banned Hemp-THC Products

Alaska banned delta-8 THC and other hemp-derived intoxicating cannabinoids in 2022 by adding them to the state's controlled substances schedule. The state's adult-use cannabis program provides legal access to tested marijuana products, and regulators cited concerns about unregulated competition. Colorado restricted hemp-derived THC products in 2022 by requiring they be sold only through licensed marijuana dispensaries and limiting concentrations to 0.3% total THC per package. The restriction effectively eliminated the standalone hemp-THC market while preserving access through the regulated cannabis system. Delaware banned delta-8 THC in 2022, with the state's Division of Public Health adding it to Schedule I. The ban preceded the state's adult-use legalization, which took effect in 2023. Kentucky banned delta-8 THC in 2023 despite being a major hemp-producing state. The Kentucky Department of Agriculture determined that chemically converted cannabinoids did not qualify as legal hemp under state law. Montana banned hemp-derived THC products in 2021 by clarifying that all THC isomers are controlled substances regardless of source. The state's adult-use cannabis program provides alternative legal access. New York restricted hemp-THC sales in 2022 by requiring products be sold only through licensed cannabis retailers and meet state testing standards. The restriction took effect as the state's adult-use market launched. Oregon banned delta-8 THC in 2021, with the Oregon Liquor and Cannabis Commission determining that intoxicating hemp products must be sold through licensed cannabis retailers and meet marijuana testing standards. Rhode Island banned delta-8 THC in 2021 by adding it to the state's controlled substances list. The ban preceded adult-use legalization, which took effect in 2022. Vermont banned delta-8 THC in 2021, with the state's Cannabis Control Board determining that all intoxicating THC products must be sold through licensed cannabis retailers. Washington banned delta-8 THC in 2022 by clarifying that all forms of THC are controlled substances unless sold through the state's licensed cannabis system.

States That Allow Hemp-THC Products with Regulations

Alabama allows hemp-THC products but requires retailers to register with the state and verify purchaser age as 21 or older. Products must be derived from hemp containing less than 0.3% delta-9 THC. Georgia allows hemp-THC sales under the 2019 Georgia Hemp Farming Act but has proposed regulations requiring testing and labeling. As of May 2026, specific regulations have not been finalized. Louisiana allows hemp-THC products under Act 164 (2022), which created a regulatory framework including age restrictions, testing requirements, and licensing for manufacturers and retailers. Minnesota legalized hemp-THC edibles in 2022 with specific concentration limits: products cannot exceed 5 mg THC per serving or 50 mg per package. The law requires testing, labeling, and age verification. North Carolina allows hemp-THC products under the 2022 Farm Act, which established testing and labeling requirements and prohibited sales to individuals under 21. South Carolina allows hemp-THC products without specific state regulations beyond federal hemp law compliance, creating one of the least restrictive markets. Tennessee allows hemp-THC products but has proposed regulations requiring testing, labeling, and age verification. The state's regulatory approach remains in development as of May 2026.

States with Unclear or Evolving Status

Florida has not enacted a statewide ban, but individual counties and cities have passed local prohibitions. The state's hemp program allows products derived from hemp containing less than 0.3% delta-9 THC, but regulatory clarity remains limited. Florida's adult-use legalization ballot measure, which failed in November 2024, would have provided clearer regulatory authority. Michigan allows hemp-THC products under federal hemp law but has not created specific state regulations. The state's Cannabis Regulatory Agency has indicated that intoxicating hemp products may eventually require cannabis licensing, but enforcement has been limited. Ohio allows hemp-THC products under the 2019 hemp law but has proposed regulations that would restrict sales to licensed cannabis retailers following adult-use legalization in 2024. Texas remains in legal limbo, with hemp-THC products legal under court injunction but subject to ongoing litigation over DSHS's ban attempt.

Market and Business Implications

A successful Texas ban would eliminate $800 million in annual sales, force closure of thousands of small businesses, and reshape national hemp-THC supply chains. The immediate impact would fall on Texas's estimated 2,400 hemp-THC retailers, ranging from dedicated CBD stores to vape shops, smoke shops, and convenience stores. Industry surveys indicate that hemp-THC products represent 60-80% of revenue for specialty retailers that pivoted from CBD sales when that market commoditized. A ban would render existing inventory worthless overnight—retailers collectively hold an estimated $120 million in hemp-THC products that would become unsellable. Small business owners face particularly acute risk. Unlike multi-state operators that can shift inventory to other markets, independent Texas retailers have no alternative distribution channels. Many operators invested life savings and took on debt to build businesses around products that were legal when they launched. The lack of a phase-out period or buyback program means these investments would be total losses. Upstream manufacturers and distributors would face cascading impacts. Texas-based hemp processors including Hometown Hero, Bayou City Hemp Company, and Moonwalk Brands generate tens of millions in annual revenue from Texas sales. These companies employ chemists, production workers, quality control staff, and distribution personnel whose jobs depend on the Texas market. Manufacturers also face the challenge of reformulating product lines or exiting the hemp-THC category entirely if Texas establishes a precedent that other states follow. Hemp farmers represent another affected stakeholder group. Texas issued over 3,000 hemp cultivation licenses since 2019, with farmers planting approximately 8,500 acres in 2025 according to Texas Department of Agriculture data. Much of this cultivation supplies the hemp-THC market—farmers grow high-CBD strains that processors convert to delta-8 and other cannabinoids. A ban would eliminate a major buyer category, depressing hemp biomass prices and making cultivation economically unviable for many farmers. The competitive implications for medical cannabis operators are significant. Texas's three licensed dispensaries have argued that hemp-THC products create unfair competition by offering intoxicating cannabis without the testing, security, and operational costs imposed on licensed operators. A ban would eliminate this competition and potentially drive consumers toward the Compassionate Use Program, though the program's restrictive qualifying conditions and 1% THC cap mean many hemp-THC users would not qualify for medical cannabis access. From an investor perspective, the Texas litigation creates uncertainty that extends beyond the state. Private equity firms and venture capital funds have invested hundreds of millions in hemp-THC companies based on the assumption that the 2018 Farm Bill created a durable legal foundation. A successful state ban upheld on appeal would undermine this thesis and could trigger down rounds, portfolio write-downs, and reduced capital availability for the sector. The wholesale pricing dynamics also face disruption. Delta-8 THC distillate traded at approximately $1,200 per kilogram in bulk markets as of May 2026, down from $3,500 per kilogram in 2022 as production scaled and competition intensified. A Texas ban would remove a major demand source, likely depressing wholesale prices further and squeezing manufacturer margins. Conversely, if the ban is struck down and other states adopt permissive regulatory frameworks, demand could accelerate and stabilize pricing. Multi-state operators in the licensed cannabis space are watching closely. Companies including Trulieve, Curaleaf, and Green Thumb Industries have largely avoided the hemp-THC category due to regulatory uncertainty, but a definitive legal framework could prompt entry. If courts establish that hemp-THC is protected by federal law, MSOs could leverage their compliance infrastructure and distribution networks to capture market share from smaller hemp companies. The tax implications are also substantial. Hemp-THC businesses currently operate outside the IRS Section 280E prohibition that prevents cannabis companies from deducting ordinary business expenses. This creates a significant cost advantage—hemp retailers can deduct rent, payroll, and other expenses that marijuana dispensaries cannot. If hemp-THC products are rescheduled or banned, this tax treatment could change, affecting business viability even in states where sales remain legal.

What Experts Say

Legal scholars, industry analysts, and public health experts offer divergent perspectives on the Texas ban's legality, policy merits, and likely outcomes. According to Rod Kight, a cannabis attorney based in North Carolina who specializes in hemp law, the 2018 Farm Bill's language is unambiguous in legalizing hemp derivatives. Kight has stated in industry presentations that the law's definition of hemp includes "all derivatives, extracts, cannabinoids" from compliant plants, and that states cannot ban products that meet federal hemp criteria without running afoul of the Supremacy Clause. He has argued that DSHS's "synthetic" distinction lacks legal foundation because chemical processes applied to legal hemp do not transform the product into a controlled substance. Shane Pennington, a cannabis attorney with Vicente Sederberg LLP who has represented hemp companies in regulatory matters, has taken a more cautious view. In legal analyses, Pennington has noted that the DEA's position on synthetically derived cannabinoids creates ambiguity that states may exploit. He has suggested that the legal outcome may turn on whether courts defer to agency interpretations under Chevron deference principles or apply independent statutory analysis. From a public health perspective, Dr. Beatriz Carlini, a research scientist at the University of Washington's Addictions, Drug & Alcohol Institute, has expressed concerns about hemp-THC products in published research. Carlini's work has documented inconsistent labeling, potency variability, and contamination in delta-8 products tested in Washington state. She has stated in academic publications that the lack of regulatory oversight creates consumer safety risks that justify state intervention, regardless of federal hemp law. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, a national hemp industry trade group, has argued that state bans undermine congressional intent in passing the 2018 Farm Bill. In testimony before state legislatures, Miller has contended that the bill aimed to create a uniform national hemp market and that state-by-state prohibitions fragment this market and harm interstate commerce. He has advocated for federal regulatory clarity from the FDA and USDA rather than state-level bans. Economists studying the hemp market have noted the industry's rapid growth and volatility. Dr. Beau Whitney, founder of Whitney Economics, a cannabis and hemp market research firm, has estimated that the U.S. hemp-THC market reached $2.8 billion in sales in 2025. Whitney's analysis has indicated that Texas represents approximately 28% of this market, making it the largest state market outside of adult-use cannabis states. He has projected that a Texas ban could reduce national hemp-THC sales by 20-25% when accounting for supply chain disruptions beyond direct Texas retail. Legal scholars have debated the federalism implications. Professor Robert Mikos of Vanderbilt Law School, who specializes in federalism and drug policy, has written that the CSA's savings clause preserving state authority creates a strong presumption against preemption. In academic articles, Mikos has argued that states retain traditional police powers to regulate intoxicating substances and that the 2018 Farm Bill's silence on state authority to ban specific hemp derivatives likely preserves that authority. Conversely, Professor Sam Kamin of the University of Denver Sturm College of Law has suggested that the 2018 Farm Bill's explicit legalization of hemp derivatives may create an implied preemption of state bans. In legal commentary, Kamin has noted that allowing states to ban federally legal hemp products creates the same type of conflict that the CSA's marijuana prohibition creates with state adult-use programs, and that courts may resolve this conflict in favor of federal law.

What's Next

The Texas hemp-THC ban's fate will be determined by court decisions in 2026-2027, potential legislative action in 2027, and possible federal regulatory intervention. The immediate timeline centers on the Travis County district court case challenging the DSHS ban. As of May 2026, the case remains in the discovery phase, with trial anticipated in late 2026 or early 2027. The temporary injunction blocking the ban will remain in effect until a final judgment, meaning hemp-THC products continue to be sold legally in Texas during litigation. If the district court rules in favor of DSHS and lifts the injunction, the ban would take immediate effect unless plaintiffs obtain an appellate stay. Hemp retailers would face a choice between immediate closure or continuing sales in violation of the ban while appealing. Industry attorneys have indicated they would seek emergency relief from the Third Court of Appeals in Austin to maintain the status quo during appeal. If the district court rules against DSHS and permanently enjoins the ban, the state would likely appeal to the Third Court of Appeals. Appellate briefing and oral argument would extend the timeline into 2027 or 2028, with the possibility of further appeal to the Texas Supreme Court if the case raises significant legal questions. The multi-year timeline creates extended uncertainty for businesses and consumers. The 2027 Texas legislative session, beginning in January 2027, represents a potential resolution path. Lawmakers could enact comprehensive hemp-THC regulation that preempts both the DSHS ban and the litigation by creating a statutory framework. Proposed approaches include age restrictions, testing requirements, potency limits, and licensing systems for manufacturers and retailers. However, the 2023 and 2025 sessions' failure to pass similar legislation suggests that political obstacles remain substantial. At the federal level, the FDA has indicated it is developing regulations for hemp-derived CBD products but has not addressed intoxicating cannabinoids. The agency issued warning letters to delta-8 manufacturers in 2022 citing unapproved food additive and drug claims, but has not pursued enforcement actions against compliant products. Congressional legislation to clarify hemp-THC regulation has been proposed but not advanced, including the Hemp and Hemp-Derived CBD Consumer Protection Act introduced in 2023. The DEA's ongoing marijuana rescheduling process could indirectly affect hemp-THC regulation. If marijuana is rescheduled from Schedule I to Schedule III as proposed in the DEA's May 2024 notice of proposed rulemaking, the legal distinction